<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-90759" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Bisphosphonate Toxicity</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Alaranji</surname>
            <given-names>Ghassan</given-names>
          </name>
          <aff>University of Auckland</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Reilly</surname>
            <given-names>Elizabeth</given-names>
          </name>
          <aff>George Washington University Medical Center Washington, D.C.</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Ghassan Alaranji declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Elizabeth Reilly declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>9</day>
          <month>1</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-90759.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Bisphosphonates emerged as a novel treatment for bone metabolism disorders in the second half of the 20th century. Currently, they are widely used in the management of cancer-related bone disease and osteoporosis. This activity reviews some of the most significant complications related to bisphosphonate toxicity and highlights the role of the interprofessional team in evaluating and treating patients with this condition.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Assess&#x000a0;the etiology of bisphosphonate toxicity.</p></list-item><list-item><p>Identify&#x000a0;the appropriate evaluation of bisphosphonate toxicity.</p></list-item><list-item><p>Evaluate&#x000a0;the management options for bisphosphonate toxicity.</p></list-item><list-item><p>Communicate&#x000a0;the importance of improving care coordination amongst interprofessional team members to enhance care delivery for patients with bisphosphonate toxicity.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=90759&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=90759">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-90759.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Bisphosphonates are the cornerstone in the management of metabolic and cancer-related bone disease. The use of bisphosphonates in patients with multiple myeloma and metastatic bone disease has led to a reduced incidence of pathological fractures.<xref ref-type="bibr" rid="article-90759.r1">[1]</xref>&#x000a0;Because of their antiresorptive qualities, bisphosphonates are widely used in the treatment of osteoporosis. Studies have shown that the use of bisphosphonates reduces the risk of vertebral and hip fractures by 30%-70% in women with osteoporosis.<xref ref-type="bibr" rid="article-90759.r2">[2]</xref>&#x000a0;Bisphosphonates first appeared on the industrial scene in the 19th century when their unique structural properties were used to soften water and prevent pipes' scaling and corrosion.<xref ref-type="bibr" rid="article-90759.r3">[3]</xref>&#x000a0;They were then introduced to medicine in the late 1960s to treat diseases that affect bone metabolism.<xref ref-type="bibr" rid="article-90759.r3">[3]</xref>&#x000a0;Etidronate and clodronic acid were the first&#x000a0;2 bisphosphonates used in medical practice.<xref ref-type="bibr" rid="article-90759.r3">[3]</xref>&#x000a0;Since then, more potent agents have been developed with increased duration of action. Bisphosphonate zoledronic acid is widely used and can be given by intravenous infusion as a single dose once a year.<xref ref-type="bibr" rid="article-90759.r4">[4]</xref>&#x000a0;Despite their benefits, bisphosphonates have both short-term and long-term side effects. A good understanding of these is essential when prescribing this class of drugs.<xref ref-type="bibr" rid="article-90759.r5">[5]</xref></p>
      </sec>
      <sec id="article-90759.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>In healthy bone, the bony tissues undergo constant remodeling. Two processes occur simultaneously: resorption of the bone executed by osteoclasts and production of new bone mediated by osteoblasts. Maintaining a healthy balance between these&#x000a0;2 processes is key to maintaining bone homeostasis.<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://aus01.safelinks.protection.outlook.com/?url=https%3A%2F%2Fwww.statpearls.com%2FKeywords%2FUserViewPopup%2F90759%23ref_9811806&#x00026;data=01%7C01%7CDebbie.Barham%40hospicewaikato.org.nz%7C0363839366d44d05f13308d7e521572a%7C6a1c9587d444405eaeb355d57ea9c5e1%7C0&#x00026;sdata=yv0YXqDV237axmPh0MHqMEdQwuQUMhQmpr%2FZvUWoCis%3D&#x00026;reserved=0">[6]</ext-link>&#x000a0;Several factors play a role in sustaining this balance. Growth factors, such as insulin-like growth factor-1 and transforming growth factor-beta, are released during the resorption phase to&#x000a0;induce the bone formation process, and other factors, such as parathyroid hormone and prostaglandin E, are thought to activate both processes simultaneously.<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://aus01.safelinks.protection.outlook.com/?url=https%3A%2F%2Fwww.statpearls.com%2FKeywords%2FUserViewPopup%2F90759%23ref_9811806&#x00026;data=01%7C01%7CDebbie.Barham%40hospicewaikato.org.nz%7C0363839366d44d05f13308d7e521572a%7C6a1c9587d444405eaeb355d57ea9c5e1%7C0&#x00026;sdata=yv0YXqDV237axmPh0MHqMEdQwuQUMhQmpr%2FZvUWoCis%3D&#x00026;reserved=0">[6]</ext-link></p>
        <p>Bisphosphonates and calcium pyrophosphates are similar in structure. In healthy bone, calcium pyrophosphates bind to calcium, forming a strong bond.<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://aus01.safelinks.protection.outlook.com/?url=https%3A%2F%2Fwww.statpearls.com%2FKeywords%2FUserViewPopup%2F90759%23ref_15724942&#x00026;data=01%7C01%7CDebbie.Barham%40hospicewaikato.org.nz%7C0363839366d44d05f13308d7e521572a%7C6a1c9587d444405eaeb355d57ea9c5e1%7C0&#x00026;sdata=bENDMIqIpGfpEg3Vp2Qpzj16D1BomJkZCK4XQGrdWnM%3D&#x00026;reserved=0">[7]</ext-link>&#x000a0;Cancer-driven osteoclasts weaken the skeleton by ingesting it. Due to the structural similarities with calcium pyrophosphates, the malignancy-activated osteoclasts ingest bisphosphonates too. This interferes with these osteoclasts' metabolism, eventually leading to cell death.<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://aus01.safelinks.protection.outlook.com/?url=https%3A%2F%2Fwww.statpearls.com%2FKeywords%2FUserViewPopup%2F90759%23ref_15724942&#x00026;data=01%7C01%7CDebbie.Barham%40hospicewaikato.org.nz%7C0363839366d44d05f13308d7e521572a%7C6a1c9587d444405eaeb355d57ea9c5e1%7C0&#x00026;sdata=bENDMIqIpGfpEg3Vp2Qpzj16D1BomJkZCK4XQGrdWnM%3D&#x00026;reserved=0">[7]</ext-link>&#x000a0;Thus, by suppressing osteoclast activity, bisphosphonates suppress bone turnover. However,&#x000a0;prolonged use of bisphosphonates is thought to be associated with over-inhibition of bone turnover, resulting in skeletal fragility and atypical fractures, especially in the femoral region&#x000a0;<xref ref-type="bibr" rid="article-90759.r6">[6]</xref>. Evidence suggests that these atypical stress fractures are caused by bisphosphonates interfering with the bone cortex's remodeling and natural healing process.<xref ref-type="bibr" rid="article-90759.r7">[7]</xref>&#x000a0;Bisphosphonate toxicity can be seen in both therapeutic dosing and overdoses. It is also independent of the renal or hepatic function of the patient. Ensuring adequate calcium and vitamin D intake before, during, and after bisphosphonate therapy limits some adverse effects, especially hypocalcemia.<xref ref-type="bibr" rid="article-90759.r8">[8]</xref></p>
      </sec>
      <sec id="article-90759.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>A&#x000a0;recent meta-analysis of 47 studies of breast cancer patients who were given intravenous bisphosphonates included 23 randomized controlled clinical trials, with the total number of patients included being 20,607. Influenza-like illness was shown to be the most common side effect of bisphosphonate use, with no observable difference between the sexes.<xref ref-type="bibr" rid="article-90759.r9">[9]</xref>&#x000a0;Other side effects were fatigue, fever, dyspepsia, and anorexia.&#x000a0;The overall incidence of ONJ was 2% compared to that of patients taking oral bisphosphonates for osteoporosis, ranging from 1 in 10,000 to 1 in 100,000 patient-years&#x000a0;<xref ref-type="bibr" rid="article-90759.r10">[10]</xref>. Atypical fractures are seen with the long-term use of bisphosphonates (median use of 7 years).&#x000a0;The absolute risk of such fractures ranges between 3.2 to 50 cases per 100000 patient-years.<xref ref-type="bibr" rid="article-90759.r7">[7]</xref></p>
      </sec>
      <sec id="article-90759.s5" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>The&#x000a0;findings from the clinical history and examination of patients with bisphosphonate toxicity depend on the complications that arise. A thorough history of exposure and a physical examination assist in making decisions about further evaluation and treatment. Given the diversity of the complications, a detailed review of systems helps identify the organs involved.</p>
        <p>
<bold>Systemic Adverse Effects</bold>
</p>
        <p>Flu-like symptoms have been observed with intravenous bisphosphonate use.<xref ref-type="bibr" rid="article-90759.r11">[11]</xref>&#x000a0;Patients experience fever, fatigue, arthralgia, myalgia, nausea, and increased bone pain.<xref ref-type="bibr" rid="article-90759.r12">[12]</xref>&#x000a0;The symptoms usually occur within 24 to 72 hours of bisphosphonate administration. Cytokine releases such as tumor necrosis factor-alpha, interferon-Y, and interleukin-6 are thought to precipitate the systemic inflammatory response.<xref ref-type="bibr" rid="article-90759.r13">[13]</xref><xref ref-type="bibr" rid="article-90759.r14">[14]</xref>&#x000a0;Treatment is usually aimed at relieving the symptoms, and the recurrence usually lessens with subsequent administrations (the risk declines from 30% with the first infusion to less than 7% in subsequent infusions.<xref ref-type="bibr" rid="article-90759.r15">[15]</xref></p>
        <p>
<bold>Upper Gastrointestinal Adverse Effects</bold>
</p>
        <p>There are several commonly encountered adverse&#x000a0;effects from the oral use of bisphosphonates. Erosive esophagitis can be seen and is thought to be related to suboptimal oral administration of bisphosphonates. Patients should be advised to ingest the drug with a full glass of water and then maintain an upright position for 30-60 minutes. The association between bisphosphonate use and nausea, dyspepsia, and abdominal pain appears to be weaker, and the occurrence of any of these symptoms should prompt further evaluation for underlying GI conditions before discontinuing the bisphosphonates. Proton pump inhibitors can be used to reduce these adverse effects.<xref ref-type="bibr" rid="article-90759.r8">[8]</xref></p>
        <p>
<bold>Hypocalcemia</bold>
</p>
        <p>Several conditions increase the risk of hypocalcemia during bisphosphonate use. Vitamin D deficiency, hypoparathyroidism, and hypomagnesemia are all predisposing factors.<xref ref-type="bibr" rid="article-90759.r5">[5]</xref>&#x000a0;The risk intensifies in cancer patients with osteoblastic bone metastases.<xref ref-type="bibr" rid="article-90759.r1">[1]</xref>&#x000a0;Clinical presentation can be variable, from nonspecific lethargy and weakness to severe tetany and seizures.<xref ref-type="bibr" rid="article-90759.r5">[5]</xref>&#x000a0;The symptoms can occur within days of the first infusion but can also be seen after months of repeated infusions.<xref ref-type="bibr" rid="article-90759.r5">[5]</xref></p>
        <p>
<bold>Ocular Complications</bold>
</p>
        <p>Even at the recommended dosing, pamidronate can cause scleritis, uveitis, and conjunctivitis.<xref ref-type="bibr" rid="article-90759.r12">[12]</xref>&#x000a0;Pain and redness in the eyes have also been reported following zoledronic acid infusion. The slit-lamp examination has confirmed uveitis in several cases.<xref ref-type="bibr" rid="article-90759.r11">[11]</xref></p>
        <p>
<bold>Osteonecrosis of the Jaw (ONJ)</bold>
</p>
        <p>ONJ is a condition characterized by the destruction of bone tissue in the jaw due to a lack of blood supply associated with infection from oral flora.<xref ref-type="bibr" rid="article-90759.r5">[5]</xref><xref ref-type="bibr" rid="article-90759.r16">[16]</xref>&#x000a0;The first documented case of ONJ was in 2003. The overall incidence of ONJ is 1% to 10%, and cancer patients represent the majority.<xref ref-type="bibr" rid="article-90759.r5">[5]</xref>&#x000a0;2 main factors influence&#x000a0;the likelihood of developing ONJ. The first&#x000a0;1 is the type and total dose of bisphosphonates. The more potent the drug and longer the drug is used, the higher&#x000a0;the risk of ONJ.&#x000a0;Also, the risk is 15-fold higher with intravenous bisphosphonates than oral bisphosphonates.<xref ref-type="bibr" rid="article-90759.r16">[16]</xref><xref ref-type="bibr" rid="article-90759.r17">[17]</xref>&#x000a0;The second factor is previous dental trauma, such as dental extractions or surgery, and oral infections.<xref ref-type="bibr" rid="article-90759.r17">[17]</xref>&#x000a0;Pain and exposed bone are the most common presenting features.<xref ref-type="bibr" rid="article-90759.r5">[5]</xref>&#x000a0;Some patients report pain and numbness, with or without soft tissue swelling and tooth mobility.<xref ref-type="bibr" rid="article-90759.r18">[18]</xref>&#x000a0;However, a third of the cases are painless.<xref ref-type="bibr" rid="article-90759.r19">[19]</xref>&#x000a0;Rarely do patients present with fractures and fistula formation.<xref ref-type="bibr" rid="article-90759.r5">[5]</xref>&#x000a0;Imaging is usually not helpful as radiographic features are nonspecific. Suggestive history and typical clinical signs and symptoms with concurrent use of bisphosphonates are usually sufficient to make the diagnosis.<xref ref-type="bibr" rid="article-90759.r5">[5]</xref></p>
        <p>
<bold>Subtrochanteric Femoral Fractures</bold>
</p>
        <p>Although not clearly shown in clinical trials, several case reports describe the association between bisphosphonates and subtrochanteric femoral fractures. These typically occur either spontaneously or following low-impact trauma. They are located in the proximal or mid-femoral diaphysis and are seen in patients on long-term treatment with bisphosphonates. They should be suspected in patients who report vague femoral pain or weakness. Recent reports, however, refute the association with bisphosphonate use. Rather, they propose that subtrochanteric femoral fractures are an uncommon type of osteoporotic fracture or a manifestation of rare metabolic bone disorders, such as adult hypophosphatasia. Imaging helps diagnose this condition, and referral to a metabolic bone disease specialist may be useful.<xref ref-type="bibr" rid="article-90759.r8">[8]</xref></p>
      </sec>
      <sec id="article-90759.s6" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>Laboratory studies provide further information when diagnosing complications of bisphosphonate use. For instance, low hemoglobin can be seen with erosive esophagitis. Calcium and vitamin D levels can help identify hypocalcemia, and rising creatinine is key in diagnosing nephrotoxicity.&#x000a0;Plain X-rays can show atypical femoral fractures appearing transversely, sometimes obliquely, and with a "beaked" appearance on the cortex. The technetium (Tc)-99m bone scan shows increased uptake in the affected area. Magnetic resonance imaging can be useful in cases with a negative X-ray and a high clinical suspicion. A low signal fracture line in T1, T2, and short TI inversion recovery (STIR) images can be seen, while the marrow signal appears low in T1 and high in T2 and STIR.</p>
      </sec>
      <sec id="article-90759.s7" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>
<bold>Management of Acute-phase Reactions</bold>
</p>
        <p>These systemic reactions are typically self-limiting. The mainstay of management is the supportive use of acetaminophen with or without nonsteroidal anti-inflammatory drugs. Acute-phase reactions normally resolve within 48 hours. Premedication with acetaminophen&#x000a0;is advised with recurrent doses. It is important to rule out other causes of fever, such as infection.<xref ref-type="bibr" rid="article-90759.r5">[5]</xref>&#x000a0;</p>
        <p>
<bold>Management of Upper GI Adverse Effects</bold>
</p>
        <p>As mentioned earlier, proper drug administration can prevent the occurrence of these complications. However, the use of bisphosphonates should be avoided in patients who have chronic esophageal conditions, such as Barrett's esophagus.&#x000a0;</p>
        <p>
<bold>Management of Hypocalcemia</bold>
</p>
        <p>Managing hypocalcemia in the context of bisphosphonate use involves identifying leading causes, such as previous radiotherapy to the head and neck, prior thyroidectomy, and hypomagnesemia.<xref ref-type="bibr" rid="article-90759.r5">[5]</xref>&#x000a0;If hypocalcemia is present, it should be corrected and then monitored during therapy.<xref ref-type="bibr" rid="article-90759.r5">[5]</xref>&#x000a0;Correction of pre-existing hypocalcemia or vitamin D deficiency is strongly recommended before initiating bisphosphonates.</p>
        <p>
<bold>Management of Ocular Complications</bold>
</p>
        <p>Ocular complications are rare and usually not vision-threatening. However, a referral to an ophthalmologist is recommended to manage ocular complications.<xref ref-type="bibr" rid="article-90759.r5">[5]</xref></p>
        <p>
<bold>Management of ONJ</bold>
</p>
        <p>Prevention and early identification of high-risk patients are key strategies in the management of ONJ.<xref ref-type="bibr" rid="article-90759.r20">[20]</xref>&#x000a0;If necessary, a dental check-up and treatment are essential before starting bisphosphonates in high-risk patients. Patients should also be informed of the risk of developing this condition and the benefit of ongoing prophylactic dental care.<xref ref-type="bibr" rid="article-90759.r20">[20]</xref><xref ref-type="bibr" rid="article-90759.r21">[21]</xref>&#x000a0;A drug holiday has also been suggested as a prophylactic measure to reduce the risk of developing ONJ. It is defined as a temporary cessation of the drug before a planned dentoalveolar procedure.<xref ref-type="bibr" rid="article-90759.r22">[22]</xref>&#x000a0;Once ONJ occurs, management becomes challenging.<xref ref-type="bibr" rid="article-90759.r20">[20]</xref>&#x000a0;Depending on how advanced the condition is, treatment ranges from conservative care to surgical debridement and resection of the involved tissues. Conservative care consists mainly of regular dentist visits, the use of chlorhexidine mouthwash, and antibiotic treatment for infections.<xref ref-type="bibr" rid="article-90759.r20">[20]</xref>&#x000a0;The surgical&#x000a0;approach is confined to cases where the conservative approach fails, or bone exposure is present.<xref ref-type="bibr" rid="article-90759.r23">[23]</xref>&#x000a0;Adjunctive modalities have been trialed, such as oxygen therapy and using mesenchymal cells to recreate bone tissue.<xref ref-type="bibr" rid="article-90759.r20">[20]</xref></p>
        <p>
<bold>Management of Subtrochanteric Femoral Fractures</bold>
</p>
        <p>Bisphosphonates should be discontinued upon confirmation of the fracture, and calcium and vitamin D supplementation should be considered. Depending on the imaging findings, an orthopedic referral shall be sought.</p>
      </sec>
      <sec id="article-90759.s8" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>It is important to&#x000a0;be&#x000a0;mindful of other conditions with a similar radiographic appearance as ONJ, such as radiation-induced osteonecrosis and infections.<xref ref-type="bibr" rid="article-90759.r24">[24]</xref>&#x000a0;Differential diagnoses for atypical femoral fractures include trauma, osteoarthritis, and inflammatory arthritis.</p>
      </sec>
      <sec id="article-90759.s9" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>The prognosis varies depending on the complications seen. While flu-like symptoms are benign and self-limiting, erosive esophagitis, ONJ, and nephrotoxicity are serious complications that can cause significant morbidity and mortality.</p>
      </sec>
      <sec id="article-90759.s10" sec-type="Complications">
        <title>Complications</title>
        <p>
<bold>Nephrotoxicity</bold>
</p>
        <p>Particular caution should be considered while giving bisphosphonates to patients with pre-existing renal impairment.<xref ref-type="bibr" rid="article-90759.r25">[25]</xref>&#x000a0;The risk of renal toxicity is increased in cancer patients who are receiving chemotherapy.<xref ref-type="bibr" rid="article-90759.r5">[5]</xref><xref ref-type="bibr" rid="article-90759.r25">[25]</xref>&#x000a0;Bisphosphonates usually affect the kidneys by causing acute tubular necrosis. Biochemically, this can be detected by a gradual rise in creatinine levels over several months. Discontinuation of the drug usually results in normalization of the kidney function within months.<xref ref-type="bibr" rid="article-90759.r26">[26]</xref>&#x000a0;Amongst the available bisphosphonates, zoledronic acid carries the highest risk of causing renal failure.<xref ref-type="bibr" rid="article-90759.r11">[11]</xref>&#x000a0;The risk becomes even greater with higher doses and&#x000a0;longer infusion time.<xref ref-type="bibr" rid="article-90759.r27">[27]</xref>&#x000a0;Zoledronic acid affects the kidneys by altering key metabolic pathways in the renal tubular cells. Microscopically, the damage is similar to that seen in acute tubular necrosis.<xref ref-type="bibr" rid="article-90759.r11">[11]</xref><xref ref-type="bibr" rid="article-90759.r28">[28]</xref>&#x000a0;Recovery from zoledronic acid kidney damage is possible but slow.<xref ref-type="bibr" rid="article-90759.r28">[28]</xref></p>
        <p>Nephrotoxicity from pamidronate, however, presents clinically as nephrotic syndrome.<xref ref-type="bibr" rid="article-90759.r11">[11]</xref>&#x000a0;Microscopically, the findings vary between focal segmental glomerulosclerosis, acute tubular injury, and minimal change disease without involving the glomeruli.<xref ref-type="bibr" rid="article-90759.r29">[29]</xref>&#x000a0;These changes are usually non-reversible&#x000a0;<xref ref-type="bibr" rid="article-90759.r11">[11]</xref>&#x000a0;and are typically seen in patients receiving the maximum recommended dose (90 mg).<xref ref-type="bibr" rid="article-90759.r30">[30]</xref>&#x000a0;Pamidronate-related nephrotic syndrome, especially if associated with renal failure, carries a poor prognosis.<xref ref-type="bibr" rid="article-90759.r11">[11]</xref>&#x000a0;Only one-fifth of the patients recover their renal function, and about 50% eventually require renal replacement therapy.<xref ref-type="bibr" rid="article-90759.r11">[11]</xref>&#x000a0;Therefore, early detection and discontinuation of pamidronate is the most important step in management.<xref ref-type="bibr" rid="article-90759.r11">[11]</xref>&#x000a0;Prevention and early detection of renal failure are key in managing bisphosphonate-related nephrotoxicity. Preventative measures include pre-infusion serum creatinine checks, adequate hydration, avoiding simultaneous use of nephrotoxic medications, and dose adjustments in patients with mild renal insufficiency.<xref ref-type="bibr" rid="article-90759.r5">[5]</xref><xref ref-type="bibr" rid="article-90759.r31">[31]</xref>&#x000a0;Generally, zoledronic acid and pamidronate are not recommended if creatinine clearance is less than 30 mL/min or if serum creatinine doubles from baseline.<xref ref-type="bibr" rid="article-90759.r5">[5]</xref><xref ref-type="bibr" rid="article-90759.r11">[11]</xref>&#x000a0;Once nephrotoxicity occurs, the first step in management is discontinuing the bisphosphonate. Management is mostly supportive, as no specific treatment has shown benefit.<xref ref-type="bibr" rid="article-90759.r11">[11]</xref>&#x000a0;Restarting the medication is possible if the benefit outweighs the risk but shall be considered on a case-by-case basis after a detailed discussion with the patient.<xref ref-type="bibr" rid="article-90759.r5">[5]</xref></p>
        <p>
<bold>Atrial Fibrillation</bold>
</p>
        <p>An association between atrial fibrillation and bisphosphonate use has been proposed. Large clinical trials, such as the Fracture Intervention Trial and the HORIZON Pivotal Fracture Trial, have reported an increased risk of developing&#x000a0;atrial fibrillation (1.3% risk in the zoledronic group versus 0.5% in the placebo group). However, several observational studies that found no association followed this. In conclusion, the retrospective trials investigating the link found the evidence neither positive nor completely ruled out. It should be noted that bisphosphonates are usually given to elderly patients with pre-existing comorbidities, including atrial fibrillation. Further trials could&#x000a0;clarify this association.<xref ref-type="bibr" rid="article-90759.r32">[32]</xref></p>
      </sec>
      <sec id="article-90759.s11" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>Before starting a bisphosphonate, a discussion of the possible adverse effects and toxicities needs to be held with patients. Risk assessment is key in managing patients who are candidates for bisphosphonates. A discussion within and amongst the healthcare and dental professional teams further helps to select appropriate patients in whom the benefits of bisphosphonates&#x000a0;outweigh the associated risks.<xref ref-type="bibr" rid="article-90759.r8">[8]</xref></p>
      </sec>
      <sec id="article-90759.s12" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Bisphosphonate use is becoming a cornerstone in managing metastatic bone disease and osteoporosis. As with any medication, bisphosphonate use can cause toxicity.&#x000a0;Clinicians need to be mindful of these toxic side effects. Regular check-ups, routine physical examinations, and frequent blood tests are key in the ongoing management of patients receiving bisphosphonates. This is best achieved with an interprofessional team approach. Prompt recognition of toxicities is important in improving outcomes. Providing education to patients and families before and during treatment with bisphosphonates can also improve patient outcomes by early detection of toxicities.&#x000a0;Interprofessional team input is essential in managing toxicities once they occur.</p>
      </sec>
      <sec id="article-90759.s13">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=90759&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=90759">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/medications/bisphosphonate-toxicity/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=90759">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/90759/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=90759">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-90759.s14">
        <title>References</title>
        <ref id="article-90759.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>von Moos</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Strasser</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Gillessen</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Zaugg</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Metastatic bone pain: treatment options with an emphasis on bisphosphonates.</article-title>
            <source>Support Care Cancer</source>
            <year>2008</year>
            <month>Oct</month>
            <volume>16</volume>
            <issue>10</issue>
            <fpage>1105</fpage>
            <page-range>1105-15</page-range>
            <pub-id pub-id-type="pmid">18682990</pub-id>
          </element-citation>
        </ref>
        <ref id="article-90759.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Delmas</surname>
                <given-names>PD</given-names>
              </name>
            </person-group>
            <article-title>Treatment of postmenopausal osteoporosis.</article-title>
            <source>Lancet</source>
            <year>2002</year>
            <month>Jun</month>
            <day>08</day>
            <volume>359</volume>
            <issue>9322</issue>
            <fpage>2018</fpage>
            <page-range>2018-26</page-range>
            <pub-id pub-id-type="pmid">12076571</pub-id>
          </element-citation>
        </ref>
        <ref id="article-90759.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Widler</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Jaeggi</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Glatt</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>M&#x000fc;ller</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Bachmann</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Bisping</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Born</surname>
                <given-names>AR</given-names>
              </name>
              <name>
                <surname>Cortesi</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Guiglia</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Jeker</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Klein</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Ramseier</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Schmid</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Schreiber</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Seltenmeyer</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Green</surname>
                <given-names>JR</given-names>
              </name>
            </person-group>
            <article-title>Highly potent geminal bisphosphonates. From pamidronate disodium (Aredia) to zoledronic acid (Zometa).</article-title>
            <source>J Med Chem</source>
            <year>2002</year>
            <month>Aug</month>
            <day>15</day>
            <volume>45</volume>
            <issue>17</issue>
            <fpage>3721</fpage>
            <page-range>3721-38</page-range>
            <pub-id pub-id-type="pmid">12166945</pub-id>
          </element-citation>
        </ref>
        <ref id="article-90759.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Reid</surname>
                <given-names>IR</given-names>
              </name>
              <name>
                <surname>Brown</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Burckhardt</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Horowitz</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Richardson</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Trechsel</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Widmer</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Devogelaer</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Kaufman</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Jaeger</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Body</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Brandi</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Broell</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Di Micco</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Genazzani</surname>
                <given-names>AR</given-names>
              </name>
              <name>
                <surname>Felsenberg</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Happ</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Hooper</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Ittner</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Leb</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Mallmin</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Murray</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Ortolani</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Rubinacci</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Saaf</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Samsioe</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Verbruggen</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Meunier</surname>
                <given-names>PJ</given-names>
              </name>
            </person-group>
            <article-title>Intravenous zoledronic acid in postmenopausal women with low bone mineral density.</article-title>
            <source>N Engl J Med</source>
            <year>2002</year>
            <month>Feb</month>
            <day>28</day>
            <volume>346</volume>
            <issue>9</issue>
            <fpage>653</fpage>
            <page-range>653-61</page-range>
            <pub-id pub-id-type="pmid">11870242</pub-id>
          </element-citation>
        </ref>
        <ref id="article-90759.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Prommer</surname>
                <given-names>EE</given-names>
              </name>
            </person-group>
            <article-title>Toxicity of bisphosphonates.</article-title>
            <source>J Palliat Med</source>
            <year>2009</year>
            <month>Nov</month>
            <volume>12</volume>
            <issue>11</issue>
            <fpage>1061</fpage>
            <page-range>1061-5</page-range>
            <pub-id pub-id-type="pmid">19922007</pub-id>
          </element-citation>
        </ref>
        <ref id="article-90759.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gedmintas</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Solomon</surname>
                <given-names>DH</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>SC</given-names>
              </name>
            </person-group>
            <article-title>Bisphosphonates and risk of subtrochanteric, femoral shaft, and atypical femur fracture: a systematic review and meta-analysis.</article-title>
            <source>J Bone Miner Res</source>
            <year>2013</year>
            <month>Aug</month>
            <volume>28</volume>
            <issue>8</issue>
            <fpage>1729</fpage>
            <page-range>1729-37</page-range>
            <pub-id pub-id-type="pmid">23408697</pub-id>
          </element-citation>
        </ref>
        <ref id="article-90759.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shane</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Burr</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Abrahamsen</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Adler</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Brown</surname>
                <given-names>TD</given-names>
              </name>
              <name>
                <surname>Cheung</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Cosman</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Curtis</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Dell</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Dempster</surname>
                <given-names>DW</given-names>
              </name>
              <name>
                <surname>Ebeling</surname>
                <given-names>PR</given-names>
              </name>
              <name>
                <surname>Einhorn</surname>
                <given-names>TA</given-names>
              </name>
              <name>
                <surname>Genant</surname>
                <given-names>HK</given-names>
              </name>
              <name>
                <surname>Geusens</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Klaushofer</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Lane</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>McKiernan</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>McKinney</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Ng</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Nieves</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>O'Keefe</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Papapoulos</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Howe</surname>
                <given-names>TS</given-names>
              </name>
              <name>
                <surname>van der Meulen</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Weinstein</surname>
                <given-names>RS</given-names>
              </name>
              <name>
                <surname>Whyte</surname>
                <given-names>MP</given-names>
              </name>
            </person-group>
            <article-title>Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the American Society for Bone and Mineral Research.</article-title>
            <source>J Bone Miner Res</source>
            <year>2014</year>
            <month>Jan</month>
            <volume>29</volume>
            <issue>1</issue>
            <fpage>1</fpage>
            <page-range>1-23</page-range>
            <pub-id pub-id-type="pmid">23712442</pub-id>
          </element-citation>
        </ref>
        <ref id="article-90759.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kennel</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Drake</surname>
                <given-names>MT</given-names>
              </name>
            </person-group>
            <article-title>Adverse effects of bisphosphonates: implications for osteoporosis management.</article-title>
            <source>Mayo Clin Proc</source>
            <year>2009</year>
            <month>Jul</month>
            <volume>84</volume>
            <issue>7</issue>
            <fpage>632</fpage>
            <page-range>632-7; quiz 638</page-range>
            <pub-id pub-id-type="pmid">19567717</pub-id>
          </element-citation>
        </ref>
        <ref id="article-90759.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yang</surname>
                <given-names>YL</given-names>
              </name>
              <name>
                <surname>Xiang</surname>
                <given-names>ZJ</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>WJ</given-names>
              </name>
              <name>
                <surname>Xiang</surname>
                <given-names>RL</given-names>
              </name>
            </person-group>
            <article-title>The incidence and relative risk of adverse events in patients treated with bisphosphonate therapy for breast cancer: a systematic review and meta-analysis.</article-title>
            <source>Ther Adv Med Oncol</source>
            <year>2019</year>
            <volume>11</volume>
            <fpage>1758835919855235</fpage>
            <pub-id pub-id-type="pmid">31217825</pub-id>
          </element-citation>
        </ref>
        <ref id="article-90759.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Khan</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Morrison</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Hanley</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Felsenberg</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>McCauley</surname>
                <given-names>LK</given-names>
              </name>
              <name>
                <surname>O'Ryan</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Reid</surname>
                <given-names>IR</given-names>
              </name>
              <name>
                <surname>Ruggiero</surname>
                <given-names>SL</given-names>
              </name>
              <name>
                <surname>Taguchi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Tetradis</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Watts</surname>
                <given-names>NB</given-names>
              </name>
              <name>
                <surname>Brandi</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Peters</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Guise</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Eastell</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Cheung</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Morin</surname>
                <given-names>SN</given-names>
              </name>
              <name>
                <surname>Masri</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Cooper</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Morgan</surname>
                <given-names>SL</given-names>
              </name>
              <name>
                <surname>Obermayer-Pietsch</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Langdahl</surname>
                <given-names>BL</given-names>
              </name>
              <name>
                <surname>Al Dabagh</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Davison</surname>
                <given-names>KS</given-names>
              </name>
              <name>
                <surname>Kendler</surname>
                <given-names>DL</given-names>
              </name>
              <name>
                <surname>S&#x000e1;ndor</surname>
                <given-names>GK</given-names>
              </name>
              <name>
                <surname>Josse</surname>
                <given-names>RG</given-names>
              </name>
              <name>
                <surname>Bhandari</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>El Rabbany</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Pierroz</surname>
                <given-names>DD</given-names>
              </name>
              <name>
                <surname>Sulimani</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Saunders</surname>
                <given-names>DP</given-names>
              </name>
              <name>
                <surname>Brown</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Compston</surname>
                <given-names>J</given-names>
              </name>
              <collab>International Task Force on Osteonecrosis of the Jaw</collab>
            </person-group>
            <article-title>Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus.</article-title>
            <source>J Bone Miner Res</source>
            <year>2015</year>
            <month>Jan</month>
            <volume>30</volume>
            <issue>1</issue>
            <fpage>3</fpage>
            <page-range>3-23</page-range>
            <pub-id pub-id-type="pmid">25414052</pub-id>
          </element-citation>
        </ref>
        <ref id="article-90759.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tanvetyanon</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Stiff</surname>
                <given-names>PJ</given-names>
              </name>
            </person-group>
            <article-title>Management of the adverse effects associated with intravenous bisphosphonates.</article-title>
            <source>Ann Oncol</source>
            <year>2006</year>
            <month>Jun</month>
            <volume>17</volume>
            <issue>6</issue>
            <fpage>897</fpage>
            <page-range>897-907</page-range>
            <pub-id pub-id-type="pmid">16547070</pub-id>
          </element-citation>
        </ref>
        <ref id="article-90759.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Saad</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Gleason</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Murray</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Tchekmedyian</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Venner</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Lacombe</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Chin</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Vinholes</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Goas</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>B</given-names>
              </name>
              <collab>Zoledronic Acid Prostate Cancer Study Group</collab>
            </person-group>
            <article-title>A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma.</article-title>
            <source>J Natl Cancer Inst</source>
            <year>2002</year>
            <month>Oct</month>
            <day>02</day>
            <volume>94</volume>
            <issue>19</issue>
            <fpage>1458</fpage>
            <page-range>1458-68</page-range>
            <pub-id pub-id-type="pmid">12359855</pub-id>
          </element-citation>
        </ref>
        <ref id="article-90759.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fraunfelder</surname>
                <given-names>FW</given-names>
              </name>
              <name>
                <surname>Fraunfelder</surname>
                <given-names>FT</given-names>
              </name>
            </person-group>
            <article-title>Adverse ocular drug reactions recently identified by the National Registry of Drug-Induced Ocular Side Effects.</article-title>
            <source>Ophthalmology</source>
            <year>2004</year>
            <month>Jul</month>
            <volume>111</volume>
            <issue>7</issue>
            <fpage>1275</fpage>
            <page-range>1275-9</page-range>
            <pub-id pub-id-type="pmid">15234126</pub-id>
          </element-citation>
        </ref>
        <ref id="article-90759.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dicuonzo</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Vincenzi</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Santini</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Avvisati</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Rocci</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Battistoni</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Gavasci</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Borzomati</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Coppola</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Tonini</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Fever after zoledronic acid administration is due to increase in TNF-alpha and IL-6.</article-title>
            <source>J Interferon Cytokine Res</source>
            <year>2003</year>
            <month>Nov</month>
            <volume>23</volume>
            <issue>11</issue>
            <fpage>649</fpage>
            <page-range>649-54</page-range>
            <pub-id pub-id-type="pmid">14651779</pub-id>
          </element-citation>
        </ref>
        <ref id="article-90759.r15">
          <label>15</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Ganesan</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Goyal</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Roane</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <chapter-title>Bisphosphonate</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>7</month>
            <day>3</day>
            <pub-id pub-id-type="pmid">29262103</pub-id>
          </element-citation>
        </ref>
        <ref id="article-90759.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sigua-Rodriguez</surname>
                <given-names>EA</given-names>
              </name>
              <name>
                <surname>da Costa Ribeiro</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>de Brito</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Alvarez-Pinzon</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>de Albergaria-Barbosa</surname>
                <given-names>JR</given-names>
              </name>
            </person-group>
            <article-title>Bisphosphonate-related osteonecrosis of the jaw: a review of the literature.</article-title>
            <source>Int J Dent</source>
            <year>2014</year>
            <volume>2014</volume>
            <fpage>192320</fpage>
            <pub-id pub-id-type="pmid">24868206</pub-id>
          </element-citation>
        </ref>
        <ref id="article-90759.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Clarke</surname>
                <given-names>BM</given-names>
              </name>
              <name>
                <surname>Boyette</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Vural</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Suen</surname>
                <given-names>JY</given-names>
              </name>
              <name>
                <surname>Anaissie</surname>
                <given-names>EJ</given-names>
              </name>
              <name>
                <surname>Stack</surname>
                <given-names>BC</given-names>
              </name>
            </person-group>
            <article-title>Bisphosphonates and jaw osteonecrosis: the UAMS experience.</article-title>
            <source>Otolaryngol Head Neck Surg</source>
            <year>2007</year>
            <month>Mar</month>
            <volume>136</volume>
            <issue>3</issue>
            <fpage>396</fpage>
            <page-range>396-400</page-range>
            <pub-id pub-id-type="pmid">17321866</pub-id>
          </element-citation>
        </ref>
        <ref id="article-90759.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Estilo</surname>
                <given-names>CL</given-names>
              </name>
              <name>
                <surname>Van Poznak</surname>
                <given-names>CH</given-names>
              </name>
              <name>
                <surname>Wiliams</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Bohle</surname>
                <given-names>GC</given-names>
              </name>
              <name>
                <surname>Lwin</surname>
                <given-names>PT</given-names>
              </name>
              <name>
                <surname>Zhou</surname>
                <given-names>Q</given-names>
              </name>
              <name>
                <surname>Riedel</surname>
                <given-names>ER</given-names>
              </name>
              <name>
                <surname>Carlson</surname>
                <given-names>DL</given-names>
              </name>
              <name>
                <surname>Schoder</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Farooki</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Fornier</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Halpern</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Tunick</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Huryn</surname>
                <given-names>JM</given-names>
              </name>
            </person-group>
            <article-title>Osteonecrosis of the maxilla and mandible in patients with advanced cancer treated with bisphosphonate therapy.</article-title>
            <source>Oncologist</source>
            <year>2008</year>
            <month>Aug</month>
            <volume>13</volume>
            <issue>8</issue>
            <fpage>911</fpage>
            <page-range>911-20</page-range>
            <pub-id pub-id-type="pmid">18695259</pub-id>
          </element-citation>
        </ref>
        <ref id="article-90759.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Woo</surname>
                <given-names>SB</given-names>
              </name>
              <name>
                <surname>Hellstein</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Kalmar</surname>
                <given-names>JR</given-names>
              </name>
            </person-group>
            <article-title>Narrative [corrected] review: bisphosphonates and osteonecrosis of the jaws.</article-title>
            <source>Ann Intern Med</source>
            <year>2006</year>
            <month>May</month>
            <day>16</day>
            <volume>144</volume>
            <issue>10</issue>
            <fpage>753</fpage>
            <page-range>753-61</page-range>
            <pub-id pub-id-type="pmid">16702591</pub-id>
          </element-citation>
        </ref>
        <ref id="article-90759.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>AlDhalaan</surname>
                <given-names>NA</given-names>
              </name>
              <name>
                <surname>BaQais</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Al-Omar</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Medication-related Osteonecrosis of the Jaw: A Review.</article-title>
            <source>Cureus</source>
            <year>2020</year>
            <month>Feb</month>
            <day>10</day>
            <volume>12</volume>
            <issue>2</issue>
            <fpage>e6944</fpage>
            <pub-id pub-id-type="pmid">32190495</pub-id>
          </element-citation>
        </ref>
        <ref id="article-90759.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Di Fede</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Panzarella</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Mauceri</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Fusco</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Bedogni</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Lo Muzio</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Sipmo Onj Board</surname>
              </name>
              <name>
                <surname>Campisi</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>The Dental Management of Patients at Risk of Medication-Related Osteonecrosis of the Jaw: New Paradigm of Primary Prevention.</article-title>
            <source>Biomed Res Int</source>
            <year>2018</year>
            <volume>2018</volume>
            <fpage>2684924</fpage>
            <pub-id pub-id-type="pmid">30306086</pub-id>
          </element-citation>
        </ref>
        <ref id="article-90759.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kuroshima</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Sasaki</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Sawase</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Medication-related osteonecrosis of the jaw: A literature review.</article-title>
            <source>J Oral Biosci</source>
            <year>2019</year>
            <month>Jun</month>
            <volume>61</volume>
            <issue>2</issue>
            <fpage>99</fpage>
            <page-range>99-104</page-range>
            <pub-id pub-id-type="pmid">31109863</pub-id>
          </element-citation>
        </ref>
        <ref id="article-90759.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Agrillo</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Filiaci</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Ramieri</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Riccardi</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Quarato</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Rinna</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Gennaro</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Cascino</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Mitro</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Ungari</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Bisphosphonate-related osteonecrosis of the jaw (BRONJ): 5 year experience in the treatment of 131 cases with ozone therapy.</article-title>
            <source>Eur Rev Med Pharmacol Sci</source>
            <year>2012</year>
            <month>Nov</month>
            <volume>16</volume>
            <issue>12</issue>
            <fpage>1741</fpage>
            <page-range>1741-7</page-range>
            <pub-id pub-id-type="pmid">23161050</pub-id>
          </element-citation>
        </ref>
        <ref id="article-90759.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sciubba</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Goldenberg</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Oral complications of radiotherapy.</article-title>
            <source>Lancet Oncol</source>
            <year>2006</year>
            <month>Feb</month>
            <volume>7</volume>
            <issue>2</issue>
            <fpage>175</fpage>
            <page-range>175-83</page-range>
            <pub-id pub-id-type="pmid">16455482</pub-id>
          </element-citation>
        </ref>
        <ref id="article-90759.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jackson</surname>
                <given-names>GH</given-names>
              </name>
            </person-group>
            <article-title>Renal safety of ibandronate.</article-title>
            <source>Oncologist</source>
            <year>2005</year>
            <volume>10 Suppl 1</volume>
            <fpage>14</fpage>
            <page-range>14-8</page-range>
            <pub-id pub-id-type="pmid">16264108</pub-id>
          </element-citation>
        </ref>
        <ref id="article-90759.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Diel</surname>
                <given-names>IJ</given-names>
              </name>
              <name>
                <surname>Bergner</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Gr&#x000f6;tz</surname>
                <given-names>KA</given-names>
              </name>
            </person-group>
            <article-title>Adverse effects of bisphosphonates: current issues.</article-title>
            <source>J Support Oncol</source>
            <year>2007</year>
            <season>Nov-Dec</season>
            <volume>5</volume>
            <issue>10</issue>
            <fpage>475</fpage>
            <page-range>475-82</page-range>
            <pub-id pub-id-type="pmid">18240669</pub-id>
          </element-citation>
        </ref>
        <ref id="article-90759.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Berenson</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Vescio</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Rosen</surname>
                <given-names>LS</given-names>
              </name>
              <name>
                <surname>VonTeichert</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Woo</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Swift</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Savage</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Givant</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Hupkes</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Harvey</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Lipton</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>A phase I dose-ranging trial of monthly infusions of zoledronic acid for the treatment of osteolytic bone metastases.</article-title>
            <source>Clin Cancer Res</source>
            <year>2001</year>
            <month>Mar</month>
            <volume>7</volume>
            <issue>3</issue>
            <fpage>478</fpage>
            <page-range>478-85</page-range>
            <pub-id pub-id-type="pmid">11297237</pub-id>
          </element-citation>
        </ref>
        <ref id="article-90759.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Markowitz</surname>
                <given-names>GS</given-names>
              </name>
              <name>
                <surname>Fine</surname>
                <given-names>PL</given-names>
              </name>
              <name>
                <surname>Stack</surname>
                <given-names>JI</given-names>
              </name>
              <name>
                <surname>Kunis</surname>
                <given-names>CL</given-names>
              </name>
              <name>
                <surname>Radhakrishnan</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Palecki</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Park</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Nasr</surname>
                <given-names>SH</given-names>
              </name>
              <name>
                <surname>Hoh</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Siegel</surname>
                <given-names>DS</given-names>
              </name>
              <name>
                <surname>D'Agati</surname>
                <given-names>VD</given-names>
              </name>
            </person-group>
            <article-title>Toxic acute tubular necrosis following treatment with zoledronate (Zometa).</article-title>
            <source>Kidney Int</source>
            <year>2003</year>
            <month>Jul</month>
            <volume>64</volume>
            <issue>1</issue>
            <fpage>281</fpage>
            <page-range>281-9</page-range>
            <pub-id pub-id-type="pmid">12787420</pub-id>
          </element-citation>
        </ref>
        <ref id="article-90759.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Markowitz</surname>
                <given-names>GS</given-names>
              </name>
              <name>
                <surname>Fine</surname>
                <given-names>PL</given-names>
              </name>
              <name>
                <surname>D'agati</surname>
                <given-names>VD</given-names>
              </name>
            </person-group>
            <article-title>Nephrotic syndrome after treatment with pamidronate.</article-title>
            <source>Am J Kidney Dis</source>
            <year>2002</year>
            <month>May</month>
            <volume>39</volume>
            <issue>5</issue>
            <fpage>1118</fpage>
            <page-range>1118-22</page-range>
            <pub-id pub-id-type="pmid">11979358</pub-id>
          </element-citation>
        </ref>
        <ref id="article-90759.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Desikan</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Veksler</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Raza</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Stokes</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Sabir</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>ZJ</given-names>
              </name>
              <name>
                <surname>Jagannath</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Nephrotic proteinuria associated with high-dose pamidronate in multiple myeloma.</article-title>
            <source>Br J Haematol</source>
            <year>2002</year>
            <month>Nov</month>
            <volume>119</volume>
            <issue>2</issue>
            <fpage>496</fpage>
            <page-range>496-9</page-range>
            <pub-id pub-id-type="pmid">12406092</pub-id>
          </element-citation>
        </ref>
        <ref id="article-90759.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sabino</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Mantyh</surname>
                <given-names>PW</given-names>
              </name>
            </person-group>
            <article-title>Pathophysiology of bone cancer pain.</article-title>
            <source>J Support Oncol</source>
            <year>2005</year>
            <season>Jan-Feb</season>
            <volume>3</volume>
            <issue>1</issue>
            <fpage>15</fpage>
            <page-range>15-24</page-range>
            <pub-id pub-id-type="pmid">15724942</pub-id>
          </element-citation>
        </ref>
        <ref id="article-90759.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fazmin</surname>
                <given-names>IT</given-names>
              </name>
              <name>
                <surname>Huang</surname>
                <given-names>CL</given-names>
              </name>
              <name>
                <surname>Jeevaratnam</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Bisphosphonates and atrial fibrillation: revisiting the controversy.</article-title>
            <source>Ann N Y Acad Sci</source>
            <year>2020</year>
            <month>Aug</month>
            <volume>1474</volume>
            <issue>1</issue>
            <fpage>15</fpage>
            <page-range>15-26</page-range>
            <pub-id pub-id-type="pmid">32208537</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
